BIOTECHNOLOGY FUND

	Shares	V ALUE		Shares	VALUE
COMMON STOCKS† - 99.7%					
			HEALTHCARE-PRODUCTS - 5.3%	7 020	¢ 2206272
BIOTECHNOLOGY - 71.9%	27 226	¢ 0.004.410	Bio-Techne Corp.	7,820	
Amgen, Inc.	37,236		Exact Sciences Corp.*	39,234	2,743,241 1,074,005
Regeneron Pharmaceuticals, Inc.* Gilead Sciences, Inc.	10,403 112,110	7,265,663 6,664,940	CareDx, Inc.* Pacific Biosciences of California, Inc.*,1	29,035 105,311	958,330
Vertex Pharmaceuticals, Inc.*	24,261	6,331,393		103,311	-
Moderna, Inc.*	34,621	5,963,813	Total Healthcare-Products		8,161,949
Illumina, Inc.*	16,281	5,688,581	HEALTHCARE-SERVICES - 4.6%		
Corteva, Inc.	87,699	5,040,939	Syneos Health, Inc.*	26,963	2,182,655
Biogen, Inc.*	20,112	4,235,587	ICON plc*	8,637	2,100,691
Seagen, Inc.*	26,999	3,889,206	Medpace Holdings, Inc.*	11,164	1,826,318
Horizon Therapeutics plc*	35,328	3,716,859	Invitae Corp.*	123,173	981,689
Royalty Pharma plc — Class A	93,870	3,657,175	Total Healthcare-Services		7,091,353
Alnylam Pharmaceuticals, Inc.*	20,460	3,340,913	Total Freditiente Scivices		7,051,555
Incyte Corp.*	41,060	3,260,985	Total Common Stocks		
BioNTech SE ADR*	18,791	3,204,993	(Cost \$89,527,785)		154,064,107
BioMarin Pharmaceutical, Inc.*	35,776	2,758,330		_	
United Therapeutics Corp.*	11,910	2,136,773		FACE	
Exelixis, Inc.*	93,638	2,122,773		Амоинт	_
Biohaven Pharmaceutical	,	, , , ,			
Holding Company Ltd.*	17,879	2,119,913	REPURCHASE AGREEMENTS ^{††,2} - 0.5%		
Guardant Health, Inc.*	31,778	2,104,975	J.P. Morgan Securities LLC		
Halozyme Therapeutics, Inc.*	46,517	1,855,098	issued 03/31/22 at 0.28%		
Ionis Pharmaceuticals, Inc.*	48,116	1,782,217	due 04/01/22	\$ 540,526	540,526
Ultragenyx Pharmaceutical, Inc.*	23,626	1,715,720	BofA Securities, Inc.		
Novavax, Inc.*,1	23,280	1,714,572	issued 03/31/22 at 0.25%		
Apellis Pharmaceuticals, Inc.*	33,144	1,684,047	due 04/01/22	208,186	208,186
Arrowhead Pharmaceuticals, Inc.*	35,997	1,655,502	Barclays Capital, Inc.		
Mirati Therapeutics, Inc.*	19,359	1,591,697	issued 03/31/22 at 0.24%		
Denali Therapeutics, Inc.*	46,795	1,505,395	due 04/01/22	54,129	54,129
Fate Therapeutics, Inc.*	38,701	1,500,438	Total Repurchase Agreements		
Blueprint Medicines Corp.*	23,360	1,492,237	(Cost \$802,841)		802,841
Beam Therapeutics, Inc.*	24,695	1,415,024	, ,		
CRISPR Therapeutics AG*	21,887	1,373,847		SHARES	
BioCryst Pharmaceuticals, Inc.*	82,177	1,336,198			-
Iovance Biotherapeutics, Inc.*	79,525	1,324,091	SECURITIES LENDING COLLATERAL ^{†,3} - 1.0%		
Emergent BioSolutions, Inc.*	27,034	1,110,016	Money Market Fund		
Veracyte, Inc.*	37,809	1,042,394	First American Government		
ChemoCentryx, Inc.*	40,002	1,002,850	Obligations Fund — Class Z, 0.15% ⁴	1,479,660	1,479,660
Editas Medicine, Inc.*	47,563	904,648	Total Securities Lending Collateral	1, 11 2,000	
Cassava Sciences, Inc.*,1	24,135	896,374	(Cost \$1,479,660)		1,479,660
TG Therapeutics, Inc.*	92,130	876,156	(Cost \$1,475,000)		1,479,000
NeoGenomics, Inc.*	65,307	793,480	Total Investments - 101.2%		
Total Biotechnology		111,080,222	(Cost \$91,810,286)		\$ 156,346,608
PHARMACEUTICALS - 17.9%			Other Assets & Liabilities, net - (1.2)%		(1,779,924)
AbbVie, Inc.	80,819	13,101,568	Total Net Assets - 100.0%		\$ 154,566,684
AstraZeneca plc ADR	47,291	3,137,285			
Viatris, Inc.	253,652	2,759,734			
Neurocrine Biosciences, Inc.*	24,201	2,268,844			
Sarepta Therapeutics, Inc.*	25,520	1,993,622			
Intellia Therapeutics, Inc.*	24,036	1,746,696			
Jazz Pharmaceuticals plc*	10,613	1,652,125			
Ironwood Pharmaceuticals,					
Inc. — Class A*	85,112	1,070,709			
Total Pharmaceuticals		27,730,583			

BIOTECHNOLOGY FUND

- * Non-income producing security.
- † Value determined based on Level 1 inputs.
- †† Value determined based on Level 2 inputs.
- $^{\rm 1}$ All or a portion of this security is on loan at March 31, 2022.
- ² Repurchase Agreements.
- ³ Securities lending collateral.
- $^{\rm 4}$ Rate indicated is the 7-day yield as of March 31, 2022.

ADR — American Depositary Receipt

plc — Public Limited Company